KRAS and non-small cell lung carcinoma: On top of this, KRAS-mutant NSCLC expressed more PD-L1, and as mentioned above, the high expression of PD-L1 was confirmed to be related to better therapeutic effect (Mazieres et al. 2019; Rizvi et al. 2018).